Daily Cosmetic Research Analysis
Three high-impact studies span mechanistic, perioperative, and oncologic domains in cosmetic-related care. A mechanistic paper identifies NRP1-driven endothelial-to-mesenchymal transition as a target to normalize scar vasculature and prevent fibrotic scarring, while a multicenter cohort suggests a standardized fractional ultra-pulse CO2 laser protocol may reduce surgical-site infections and improve scars. A national multicentre study provides the largest evidence base for managing breast cancer
Summary
Three high-impact studies span mechanistic, perioperative, and oncologic domains in cosmetic-related care. A mechanistic paper identifies NRP1-driven endothelial-to-mesenchymal transition as a target to normalize scar vasculature and prevent fibrotic scarring, while a multicenter cohort suggests a standardized fractional ultra-pulse CO2 laser protocol may reduce surgical-site infections and improve scars. A national multicentre study provides the largest evidence base for managing breast cancer in patients with prior augmentation.
Research Themes
- Scar pathophysiology and vascular normalization
- Perioperative laser protocols to reduce SSIs and improve scars
- Oncologic management in patients with prior cosmetic breast augmentation
Selected Articles
1. Targeting NRP1 in Endothelial Cells Facilitates the Normalization of Scar Vessels and Prevents Fibrotic Scarring.
Using multi-modal analyses and scRNA-seq, the study identifies an NRP1-high endothelial subset driving endothelial-to-mesenchymal transition and abnormal scar vasculature. Inhibiting NRP1 normalizes vessels and prevents scarring in mice, and a peptide-loaded hydrogel spray translates this mechanism into a tractable anti-scar strategy.
Impact: This work uncovers a mechanistic driver of scar vasculopathy and provides a targeted, translatable intervention. It may shift paradigms from vessel ablation to vascular normalization in scar prevention.
Clinical Implications: NRP1-targeted approaches could become adjuncts to surgical and laser therapies to prevent hypertrophic scars and keloids by normalizing vasculature rather than ablating it.
Key Findings
- Scars exhibit increased neovascular density, branching complexity, and incomplete wall coverage by dermatoscopy/SEM/IF.
- Single-cell RNA-seq revealed an NRP1-high endothelial subset with mesenchymal traits and upregulated oxidative phosphorylation.
- NRP1 knockdown blocked TGF-β/SMAD2 signaling, reduced EndMT, normalized vascular function, and prevented scarring in mice.
- An NRP1-targeting peptide hydrogel spray effectively prevented scar formation by promoting vascular normalization.
Methodological Strengths
- Integrated dermatoscopy, SEM, immunofluorescence, and single-cell RNA sequencing to define vascular heterogeneity.
- Mechanistic validation with in vitro knockdown and in vivo functional outcomes including prevention of scar formation.
Limitations
- Preclinical mouse models may not fully capture human scar biology and heterogeneity.
- Safety, dosing, and delivery parameters for NRP1-targeting peptide hydrogel in humans remain untested.
Future Directions: Conduct phase I/II clinical trials of NRP1-targeted topical systems in high-risk scar populations; map NRP1-EC prevalence across scar subtypes and stages; evaluate combination with laser/surgical protocols.
Current clinical treatments for skin scars primarily reduce vascular density in situ. But, outcomes remain unsatisfactory due to limited understanding of scar vascular structure, endothelial cell (EC) heterogeneity, and functional changes. Through dermatoscopy, scanning electron microscopy, and immunofluorescence staining, our study revealed substantial vascular remodeling in scars, including increased neovascularization density, branching complexity, and incomplete vascular wall coverage. Single-cell sequencing constructed an EC atlas of scar patients, identifying upregulated ATP synthesis, decomposition, and oxidative phosphorylation in scar ECs-characteristics resembling tumor vasculature. Notably, a subset of ECs with high neuropilin-1 (NRP1) expression exhibited mesenchymal characteristics. In vitro experiments demonstrated that NRP1 knockdown blocked the transforming growth factor-beta (TGF-β)/SMAD family member 2 (SMAD2) signaling pathway and mitigated endothelial-to-mesenchymal transition (EndMT). Importantly, NRP1 inhibition reduced EndMT, restored normal vascular function and structure, and prevented scar formation in mice. Based on these findings, a functional hydrogel spray was developed using an NRP1-targeting peptide, effectively preventing scar formation by promoting vascular normalization.
2. Breast Cancer After Breast Augmentation study (BCABA): A national multicentre collaborative study of patient management and outcomes.
In the largest series worldwide, breast-conserving surgery after augmentation had re-excision rates comparable to national standards, with most patients retaining or exchanging implants and receiving radiotherapy. Mastectomy with immediate reconstruction showed acceptable complication rates, informing surgical decision-making in this growing cohort.
Impact: Defines real-world outcomes and practice variation for an increasingly common scenario, providing data to guide multidisciplinary planning and patient counseling.
Clinical Implications: Breast-conserving surgery is feasible with acceptable re-excision rates; implant retention/exchange and planned radiotherapy are common. Immediate reconstruction after mastectomy is reasonable with low short-term complication rates.
Key Findings
- Among 200 affected breasts, 71.5% underwent BCS; 18.9% required re-excision and 2.1% had completion mastectomy.
- T2 tumors had higher re-excision rates than T1 or T3 (p=0.003).
- In BCS cases, 87.4% retained or exchanged implants and 91.6% were recommended radiotherapy.
- 28.5% underwent mastectomy; 68.4% received immediate reconstruction; 5 patients reoperated within 90 days (2 implant losses).
Methodological Strengths
- National multicentre cohort spanning 12 years with the largest sample to date in this population.
- Granular operative and adjuvant therapy data enabling practice pattern and outcome comparisons.
Limitations
- Retrospective design with potential selection and information biases.
- Heterogeneity in imaging, surgical techniques, and adjuvant protocols across centres.
Future Directions: Prospective registries with standardized imaging and surgical protocols; evaluate long-term oncologic and reconstructive outcomes including capsular contracture and radiation effects.
BACKGROUND: The incidence of breast cancer diagnosis in patients with previous cosmetic breast augmentation is increasing, and poses challenges in management. Given the uncertainty in how to manage these patients, we aimed to evaluate current UK practice in this patient group, encompassing both breast conserving surgery (BCS) and mastectomy with or without reconstruction. METHODS: Women diagnosed with invasive or in-situ breast cancer from January 2012 to January 2024 with pre-existing implant augmentation were identified and demographic, pathological, and operative data was recorded. Outcomes included imaging findings, surgical approach, complications, and adjuvant treatments. RESULTS: 196 women with 200 breasts with cancer were identified. There were 168 (84.0 %) patients who presented symptomatically and 28 (14.0 %) via the NHS breast screening programme. 143 (71.5 %) breasts underwent BCS of which 27 (18.9 %) required further margin re-excision and 3 (2.1 %) had completion mastectomy. Patients with T2 tumours had higher rates of margin re-excision compared to patients with T1 and T3 tumours [p = 0.003]. Within the BCS group, 125 (87.4 %) retained or exchanged an implant and 91.6 % of these patients were recommended for radiotherapy. 57 (28.5 %) breasts underwent mastectomy including 39 (68.4 %) that were reconstructed. Of the entire cohort, 5 patients returned to theatre within 90 days for a complication, including 2 implant losses. CONCLUSION: This is the largest reported series of these patients worldwide. There are wide variations in surgical management. Overall re-excision rates following BCS in patients with previous augmentation are comparable to national standards. Mastectomy with immediate reconstruction has an acceptable rate of complications.
3. Reduction of surgical-site infections and improvement of scar parameters with a uniform fractional ultra-pulse CO₂ laser protocol in cosmetic surgery: a five-center retrospective cohort.
Across five centers and 562 cosmetic procedures, a standardized three-stage fractional CO2 laser protocol was associated with fewer microbiologically confirmed SSIs and improved scar outcomes after IPTW balancing. The regimen is feasible perioperatively and may be broadly adoptable.
Impact: Suggests a pragmatic, scalable protocol that could address two persistent complications—SSIs and poor scarring—across diverse cosmetic procedures.
Clinical Implications: Consider integrating a three-stage fractional CO2 laser protocol (pre-incision, post-closure, day 10) alongside standard antibiotics to reduce infections and improve scarring; prospective validation is needed before routine adoption.
Key Findings
- In a 5-center cohort (n=562), 324 patients received a uniform three-stage fractional ultra-pulse CO2 laser protocol.
- After IPTW balancing, laser use was associated with reduced microbiologically confirmed SSIs and improved scar outcomes.
- Feasibility demonstrated across multiple cosmetic procedures with EMR-based eligibility and standardized antibiotics.
Methodological Strengths
- Multicenter design with sizable sample and standardized eligibility via EMR checklist.
- Use of IPTW to balance covariates and microbiological confirmation of SSIs including MALDI-TOF.
Limitations
- Retrospective observational design limits causal inference and may have residual confounding.
- Incomplete reporting of effect sizes and subgroup outcomes in the abstract.
Future Directions: Prospective randomized trials to quantify effect sizes by procedure type and pathogen; cost-effectiveness and patient-reported outcome measures over longer follow-up.
BACKGROUND: Postoperative infections and suboptimal scar outcomes remain persistent challenges in cosmetic surgery, impairing patient satisfaction and quality of life. This study evaluates whether a standardized fractional ultra-pulse CO₂ laser regimen can mitigate these complications. METHODS: A multicenter retrospective cohort enrolled 562 adults undergoing elective rhinoplasty, liposuction, breast augmentation, facelift, abdominoplasty, or Botox. Laser eligibility (incision >3 cm, Fitzpatrick I-IV, no collagen-vascular disorder) was determined by an EMR-embedded checklist; 324 patients received a uniform three-stage laser protocol (pre-incision, immediate post-closure, day 10). All patients followed a five-day antibiotic regimen (oral cefalexin + topical mupirocin). Baseline covariates were balanced via IPTW. SSIs were microbiologically confirmed (aerobic, anaerobic, fungal, mycobacterial cultures with MALDI-TOF). Comparative analyses used Welch's RESULTS: Of 562 patients, 324 (58%) received laser therapy. Baseline demographics and comorbidities were balanced across groups (all CONCLUSION: Standardized fractional ultra-pulse CO₂ laser therapy reduces SSIs, improves scar outcomes, and enhances patient satisfaction in cosmetic surgery. These findings support wider adoption of laser protocols, warranting further prospective, pathogen-specific research.